Amundi’s Enanta Pharmaceuticals ENTA Stock Holding History

Amundi’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,982	Closed	-$19.1K	–	2021
2023 Q3	$19.1K	Sell	1,982 -2,352	-54%	-$37.9K	﹤0.01%	1937
2023 Q2	$95.9K	Sell	4,334 -299	-6%	-$8.81K	﹤0.01%	1781
2023 Q1	$178K	Buy	+4,633	New	+$221K	﹤0.01%	1598

Other funds holding ENTA

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Amundi's ENTA Position: Q4 2023 in Review

Amundi sold out of Enanta Pharmaceuticals (ENTA) in Q4 2023, closing a stake of 1,982 shares — an estimated $19.1K sold.

Amundi first reported a position in ENTA in Q1 2023 and held it in 3 quarters. The position peaked at $178K in Q1 2023. 105 funds tracked by Wall St. Rank hold ENTA as of Q4 2023.

Amundi reported no remaining Enanta Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Amundi sold 1,982 Enanta Pharmaceuticals shares in Q4 2023, an estimated $19.1K.
Amundi first reported a position in Enanta Pharmaceuticals in Q1 2023 and held it in 3 quarters.
Amundi's Enanta Pharmaceuticals position peaked at $178K in Q1 2023.
105 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2023.

Based on Amundi's 13F filing for Q4 2023, filed 14 Feb 2024.